Statements (34)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:alsoKnownAs |
gptkb:raltegravir
|
gptkbp:approvalYear |
2007
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
J05AX08
|
gptkbp:CASNumber |
518048-05-0
|
gptkbp:developedBy |
gptkb:Merck_&_Co.
|
gptkbp:drugClass |
protease inhibitor
|
gptkbp:eliminationHalfLife |
9 hours
|
gptkbp:excretion |
urine
feces |
gptkbp:firstBook |
yes
|
gptkbp:form |
gptkb:tablet
|
gptkbp:hasMolecularFormula |
C20H20F N6O5
|
https://www.w3.org/2000/01/rdf-schema#label |
SCH 58235
|
gptkbp:KEGGID |
D08917
|
gptkbp:legalStatus |
prescription only
|
gptkbp:mechanismOfAction |
inhibits HIV integrase
|
gptkbp:metabolism |
liver (UGT1A1)
|
gptkbp:pregnancyCategory |
B (US)
|
gptkbp:proteinBinding |
83%
|
gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
54671010 DB06816 |
gptkbp:routeOfAdministration |
oral
|
gptkbp:sideEffect |
nausea
diarrhea headache insomnia |
gptkbp:synonym |
gptkb:Isentress
|
gptkbp:UNII |
80Q0TJ1W8I
|
gptkbp:usedFor |
HIV treatment
|
gptkbp:bfsParent |
gptkb:ezetimibe
|
gptkbp:bfsLayer |
6
|